SLFN11 and cancer: This review consolidates compelling evidence demonstrating that SLFN11 expression strongly correlates with increased sensitivity to a wide array of DNA-damaging agents (DDAs), including platinum compounds, topoisomerase inhibitors, and PARP inhibitors across diverse cancer types (7, 8, 11).